Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-21
    E.g., 2018-02-21

Articles

19177 items
3:24 PM, Jan 26, 2018  |  BioCentury | Finance

Tmunity’s A team

An all-star team with a proven track record in cell therapy enabled Tmunity Therapeutics Inc. to raise a $100 million series A round that included opportunistic investments from non-profits Be the Match BioTherapies and Parker...
10:56 AM, Jan 26, 2018  |  BioCentury | Emerging Company Profile

Quenching calcium

Inozyme Pharma Inc. is developing an enzyme replacement therapy that could be useful for a broad range of calcification disorders, and provide better efficacy and safety than off-label options. Its sole asset, INZ-701, is a...
4:16 PM, Jan 25, 2018  |  BioCentury | Finance

Weighing exchanges

Hua Medicine Ltd. is weighing the merits of pursuing an IPO in Hong Kong versus the U.S. ahead of the expected launch of lead candidate dorzagliatin in China. The Shanghai company’s financing strategy will be...
6:20 PM, Jan 19, 2018  |  BioCentury | Strategy

Breaking ground

The first wave of cell and gene therapies to hit the U.S. market offer the possibility of cures but also are beginning to push the limits of existing drug pricing and payment paradigms. Through new...
4:37 PM, Jan 19, 2018  |  BioCentury | Strategy

The road to precision

Roche’s deal with Syapse is the latest in a series of partnerships intended to overcome challenges associated with developing and commercializing personalized medicine for small patient populations. The partnering strategy is two-pronged: accumulate a vast...
3:15 PM, Jan 19, 2018  |  BioCentury | Finance

Deal driver

A $750 million offering from BeiGene Ltd. (NASDAQ:BGNE) should give the Chinese biotech enough financial firepower to accelerate its new in-licensing strategy and position itself as a partner of choice for innovative cancer therapies. BeiGene...
2:50 PM, Jan 19, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least seven profitable biotechs and pharmas are slated to report earnings this week. (A) Premarket on U.S. exchanges, during trading hours in Europe; (B) Fiscal 3Q CompanyDatePre/post mkt4Q17 EPS est4Q16 EPSExpected chgJohnson &...
2:04 PM, Jan 19, 2018  |  BioCentury | Finance

Under pressure

Even if rumored talks by Celgene Corp. (NASDAQ:CELG) to acquire chimeric antigen receptor (CAR) T company Juno Therapeutics Inc. (NASDAQ:JUNO) bear fruit, it still might not be enough to placate buysiders waiting for Celgene to...
11:08 AM, Jan 19, 2018  |  BioCentury | Finance

Incubating in China

C-Bridge Capital is one of the newer venture funds in Chinese healthcare seeking to bring mature platforms or programs from the Western market into China. Compared with most other Chinese VCs, however, C-Bridge is investing...
3:54 PM, Jan 18, 2018  |  BioCentury | Finance

Hatching Pandion

After scouring academia for novel treatment approaches to autoimmune and inflammatory diseases and coming up empty-handed, Polaris Partners formed Pandion Therapeutics Inc. to develop its own platform from the ground up. Backed with a $58 million...

Pages